FDA panel fails to find Vertex lumacaftor positive for cystic fibrosis

WASHINGTON, May 12 (Reuters) - A divided U.S. Food and Drug Administration advisory committee on Tuesday said research data does not show definitively that Vertex Pharmaceutical Inc's drug lumacaftor has a positive effect on cystic fibrosis patients when used in combination with the company's approved therapy, Kalydeco.